EGFR and non-small cell lung carcinoma: A large body of randomised clinical trials demonstrated the superior clinical effectiveness of EGFR TKIs compared with standard chemotherapy in patients with stage IIIB or IV NSCLC whose tumours tested positive for EGFR mutations [7–10, 13, 16, 17].